Interrad Medical last week reported raising another $5 million for its SecuraCath device, saying it hopes to raise $2 million more. SecurAcath is designed with small insertable anchors at the point of catheter entry to keep catheters from moving or coming loose in patients. The attachment device eliminates the need to suture or adhesively attach catheters. […]
Interrad Medical Inc.
Interrad Medical said today it won a Federal Supply Schedule contract with Department of Veterans Affairs and Department of Defense hospitals for its SecurAcath catheter securement device. The SecurAcath is designed with small insertable anchors at the point of catheter entry to keep catheters from moving or coming loose in patients, according to the company’s […]
Interrad Medical Inc. raised $10 million in a Series C round it plans to spend on the development and commercialization of its SecurAcath catheter stabilization device.
The private placement with high-net-worth angels backing the Minneapolis-based med-tech company was brokered by the RBC Wealth Management Group.
"Recently raising 10 million dollars, in a volatile economy, is clearly a testament to the promise of the SecurAcath technology," said Joe Goldberger, Interrad president & CEO, in prepared remarks.
MINNEAPOLIS–(BUSINESS WIRE)–Interrad Medical, Inc. a privately held medical device company, announced today that it has raised approximately $10 million in its Series C financing.
The funding was raised through a private placement by RBC Wealth Management Group in collaboration with RBC Capital Markets. RBC financial advisors and Interrad executives worked together to raise the funds exclusively from high net worth angel investors.
Bankrupt ReGen Biologics Inc. (OTC:RGBO) took out a loan from a company affiliated with one of its investors. The new debt represents Regen’s second financing deal with the company since filing for Chapter 11 bankruptcy two weeks ago.